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Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial
inflammation and joint destruction. Cell-derived small extracellular vesicles (sEV) mediate
cell-to-cell communication in the synovial microenvironment by carrying microRNAs
(miRs), a class of small non-coding RNAs. Herein, we report that sEV from synovial
fluid promote osteoclast differentiation which is attributed to high levels of extracellular
miR-574-5p. Moreover, we demonstrate for the first time that enhanced osteoclast
maturation is mediated by Toll-like receptor (TLR) 7/8 signaling which is activated by
miR-574-5p binding. This is a novel mechanism by which sEV and miRs contribute to
RA pathogenesis and indicate that pharmacological inhibition of extracellular miR-574-5p
might offer new therapeutic strategies to protect osteoclast-mediated bone destruction
in RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is one of the most common systemic autoimmune diseases,
characterized by synovial inflammation and the destruction of cartilage and bone (1). The
pathogenesis of RA is a consequence of a complex interplay between genetic and environmental
risk factors, which lead to the loss of immunological tolerance and the activation of innate and
adaptive immune responses. Increased osteoclast (OC) differentiation and activation distrupts bone
homeostasis in the course of RA (2) by altering the delicate coupling mechanisms between bone
formation and resorption (3, 4).
The synovial fluid of affected joints contain high amounts of extracellular vesicles (EV) (5).
These are membrane vesicles of endocytic origin that are actively secreted by almost all cell types
into biofluids (6) and may play an important role in the pathogenesis of RA (7). A subpopulation of
EV, termed small extracellular vesicles (sEV, 50–200 nm in diameter) (8), are involved in cell-to-cell
communication in the microenvironment of arthritic joints (9). Among other biologically active
substances, sEV contain microRNAs (miRs), a class of small non-coding RNAs (10). MiRs bind in
a sequence specific manner to their target messenger RNA (mRNA) and repress gene expression
(11, 12). In addition to this, miRs can also activate gene expression by acting as decoys to RNA-
binding proteins, thus antagonizing their functions (13, 14). Recently, an alternative function of
extracellular miRs has been described, based on their ability to induce innate immune responses.
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It was shown that sEV delivered miR-29b and miR-21 can bind
and activate toll-like receptor 7/8 (TLR7/8) in human lung cancer
(15). However, the detailed mechanism of TLR7/8 activation by
miRs is not fully understood and the pathological consequences
of this pathway have not been analyzed in RA.
In this study we demonstrate that sEV isolated from
the synovial fluid of RA patients significantly enhanced the
differentiation of OCs in vitro. Moreover, we were able
to attribute this effect to sEV delivered miR-574-5p, which
significantly increased osteoclastogenesis by activating TLR7/8
signaling. Overall, this study indentified extracellular miR-574-
5p as a critical mediator in the pathogeneis of RA and indictes
it as a promising new target for RNA therapeutics against
bone destruction.
MATERIALS AND METHODS
Cell Lines and Cell Culture Conditions
The human embryonal kidney cell line (HEK 293) (DMSZ,
ACC 035) and HeLa (DMSZ, ACC57) cells were cultured in
Dulbecco’s modified Eagle medium (DMEM, Life Technologies,
ThermoFisher Scientific, Waltham, USA) with 10% (v/v)
heat-inactivated fetal bovine serum (FBS, Life Technologies,
ThermoFisher Scientific, Waltham, USA), 100 U/ml penicillin,
100µg/ml streptomycin and 1mM sodium pyruvate (PAA the
Cell Culture Company, Cölbe, GER). Synovial fibroblasts (SFs)
of RA patients were cultured as described previously (16). This
study was approved by the Institutional Ethical Committee
(Solna, Stockholm, Sweden ethical number 2009/1262-31/3)
and is in compliance with all ethical standards and patients’
consent according to the Declaration of Helsinki. Cell culture
was carried out in a humidified atmosphere of 5% CO2 at 37
◦C.
SFs were seeded at a density of 5 × 104 cells/well in 24-well
plates and cultured in DMEM-medium supplemented with EV-
free FBS (Gibco, Life Technologies, ThermoFisher Scientific,
Waltham, USA), 100 U/ml penicillin 100µg/ml streptomycin
and 1mM sodium pyruvate for 24 h before they were stimulated
with 10 ng/ml ml interleukin (IL)-1β (Sigma-Aldrich, Darmstadt,
GER) or tumor necrosis factor α (TNF α) (Immuno Tools,
Friesoythe, GER) for further 24 h.
sEV Purification
One milliliter of cell culture supernatant, 500 µl of 1:2 diluted
serum (with phosphate buffered saline, PBS, Sigma-Aldrich,
Darmstadt, GER) or synovial fluid from RA patients were
centrifuged at 2,000 xg at room temperature for 20min. The
synovial fluid was pre-treated with hyaluronidase (1,500 U/ml;
Sigma-Aldrich, Darmstadt, GER) for 15min at 37◦C, before
sEV were isolated. The supernatant was centrifuged at 21,000
xg in 1.5ml polypropylene tubes (Beckman Coulter, Brea,
USA) at 4◦C for 60min in a L7-65 ultracentrifuge using
rotor 70.1.Ti (Beckman Coulter, Brea, USA) to remove large
membrane vesicles. The supernatant was transferred in a new
polypropylene tube and centrifuged at 100,000 xg at 4◦C for
60min. The supernatant was discarded. The remaining pellet was
resuspended in PBS. Quantity of purified sEV was determined on
protein level via UV-Vis spectroscopy to ensure treatment with
equal amounts of sEV between sEV-treatment experiments. SEV
were used directly or stored at 4◦C for not longer than 1 week.
Transmission Electron Microscopy (TEM)
SEV from human serum, HEK 293 cell culture supernatant or
synovial fluid were purified and resuspended in PBS. A drop
of purified EV was placed on parafilm and a formvar carbon
coated nickel grid (Plano, Wetzlar, GER) was placed on top
of the drop for 30–60min. The samples were fixed with 2%
paraformaldehyde (Carl Roth, Karlsruhe, GER) for 10min and
washed three times with MQ. SEV were examined using a Zeiss
EM109 electron microscope.
FACS Analysis
Samples containing sEV were thawed in a water bath for
∼5min at 37◦C. After a short vortex, 20 µl of sample were
incubated for 20min in the dark with anti-CD63 FITC (abcam,
Cambridge, UK). All samples were measured by flow cytometry
on a Beckman Gallios instrument (Beckman Coulter, Brea,
USA). Thresholds were set to side scatter in order to increase
instrument sensitivity and measurements were performed for
60 s. SEV are presented as number of events positive for CD63,
minus background noise which was determined using sEV-
free buffers (PBS). Conjugate isotype-matched immunoglobulin
(FITC) with no reactivity against human antigens was used as
negative control.
Western Blotting
Twenty to thirty microgram of purified sEV were lysed in
radioimmunoprecipitation assay buffer (RIPA), consisting
of 50mM Tris-Cl pH 7.4 (Sigma-Aldrich, Darmstadt, GER),
150mM NaCl (Sigma-Aldrich, Darmstadt, GER), 1% NP40
(Sigma-Aldrich, Darmstadt, GER), 0.25% Na-deoxycholate
(Sigma-Aldrich, Darmstadt, GER), 1mM phenylmethylsulfonyl
fluoride (Sigma-Aldrich, Darmstadt, GER), EDTA-free protease
inhibitor (Roche, Basel, CHE). SEV concentration was
determined using the NanoDrop ND-1000 spectrophotometer
(Thermo Fischer Scientific, Waltham, USA) with absorbance at
280 nm. Western blot analysis was performed according to (17).
The membranes were incubated with primary antibodies that
recognize CD63, CD9, CD81 and Heat shock protein 70 (Hsp70)
(all purchased from System Biosciences, Palo Alto, USA).
Membranes then were incubated with infrared dye conjugated
secondary antibodies (IRDye R©, LI-COR R© Bioscience, Lincoln,
USA) for 45min at room temperature. Visualization was
carried out using Odyssey Infrared Imaging System (LI-COR R©
Biosciences, Lincoln, USA).
Overexpression of miR-574-5p in sEV
The XMIRXpress Lenti system (System Biosciences, Palo Alto,
USA) was used to overexpress the level of miR-574-5p in sEV
(miR-574-5p oe). As negative control (XMIRXP-NT), which
inherits a scrambled control, was also purchased by System
Biosciences. Twenty-four hours prior to transfection HEK 293
cells were seeded at a density of 7× 105 cells/well in a 6-well plate.
Two microgram of either negative control or miR-574-5p oe
plasmid were transiently transfected using Lipofectamine 2000 R©
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(Invitrogen, Karlsruhe, GER). Supernatants were harvested for
sEV isolation after 16 h. The overexpression efficiency was
analyzed by RT-qPCR.
RNA Extraction
Total RNA from synovial fibroblasts was extracted using
miRNeasy Mini Kit (Qiagen, Hilden, GER) according to the
manufacturer’s instructions. Residual DNA was removed by on-
column DNAse digestion using RNase-Free DNase Set (Qiagen,
Hilden, GER). Total RNA from purified sEV was isolated using
the phenol/guanidinium thiocyanate (GTC)-based extraction
method according to (18). 200 nM of a non-human synthetic cel-
miR-39-3p (5′-UCACCGGGUGUAAAUCAGCUUG-3′, Sigma
Aldrich, Darmstadt, GER) was added as internal standard to
compensate for technical and methodical variations.
Real-time Quantitative PCR (RT-qPCR)
Intracellular and the extracellular miR quantification were
performed using RT-qPCR analysis according to (14, 18).
qRT-PCR was performed using the following primer: for miR-
16-5p (MS0031493), miR-146a-5p (MS00003535), miR-155-5p
(MS00031486), miR-574-5p (MS00043617, all from Qiagen,
Hilden, GER). For intracellular miR quantification snRNA U6
was used as endogenous control primer (MS00033740, Qiagen,
Hilden, GER) and as control for extracellular normalization
we used cel-miR-39-3p (MS00019789, Qiagen, Hilden,
GER). According to (14), different mRNA transcripts were
analyzed. The following primer pairs were used: Interferon
α (IFNα-fwd: 5′-GCAAGCCCAGAAGTATCTGC-3′; IFNα-
rev: 5′-CTTGACTTGCAGCTGAGCAC-3′), Interleukin
23 (IL-23-fwd: 5′-GTTCCCCATATCCAGTGTGG-3′; IL-
23-rev: 5′-AAAAATCAGACCCTGGTGGA-3′), TNFα
(TNFα_fwd: 5′- CCCAGGGACCTCTCTCTAATC-3′;
TNFα_rev: 5′- ATGGGCTACAGGCTTGTCACT-3′), IL-
1β (IL1-β-fwd: 5′-ACAGATGAAGTGCTCCTTCCA-3′;
IL1-β-rev: 5′-GTCGGAGATTCGTAGCTGGAT-3′) or IL-8
(IL-8-fwd: 5′-AGCTCTGTGTGAAGGTGCAG-3′; IL-8-rev;
5′-TGGGGTGGAAAGGTTTGGAG-3′). In all experiments
β-Actin (Actin-fwd: 5′-CGGGACCTGACTGACTAC-3′; Actin-
rev: 5′-CTTCTCCTTAATGTCACGCACG-3′) was used as
endogenous control to normalize variations in cDNA quantities
in different samples.
Live Cell Imaging
Purified sEV were labeled with lipophillic tracer 3,3′-
Dioctadecyloxacarbocy-anine perchlorate (DiO, Sigma-Aldrich,
Darmstadt, GER) for 15min at 37◦C and applied to CD14+
monocytes or HeLa cells which were stained with 5µg/ml
Hoechst 33258 (Sigma-Aldrich, Darmstadt, GER) for 30min.
Pictures were taken every 10min. Confocal images were acquired
using an UltraVIEW VoX spinning disk system (PerkinElmer,
Waltham, USA) mounted on a Nikon TI microscope (Nikon,
Minato, Japan) and equipped with a climate chamber (37◦C, 5%
CO2, 60% humidity). Images were taken at 1µm Z increments
and acquired with a cooled 14-bit EMCCD camera (1,000 ×
1,000 pixel frame transfer EMCCD, 30 fps at full frame 1 × 1
binning 35 MHz readout, 8× 8µm pixel size) using Volocity 6.3
(PerkinElmer, Waltham, USA).
RNase and TritonX 100 Treatment of sEV
Isolated miR-574-5p oe sEV were treated either with 0.05 mg/ml
RNase A (Qiagen, Hilden, GER) for 20min at 37◦C or with
1% TritonX 100 (Carl Roth, Karlsruhe, GER) for 10min at RT
and 0.05 mg/ml RNase A for 20min at 37◦C in combination.
After RNA extraction, the amount of miR-574-5p was analyzed
by RT-qPCR.
Osteoclast Differentiation
Monocytes were isolated from blood donor buffy coats using
Ficoll-PaqueTM Plus (GE Healthcare, Chicago, USA) separation
and CD14+ monocytes were selected using CD14 beads
(MiltenyiBiotec, Bergisch-Gladbach, GER) according to the
manufacturer’s instructions. 1 × 105 cells/well were seeded in
a 96-well plate in DMEM and differentiated into macrophages
using 25 ng/ml macrophage colony-stimulating factor (M-CSF,
Peprotech, Rocky Hill, USA) for 3 days. 50% of the culture
medium was changed every 3 days and cells were further
matured into OCs by medium supplements of 10 ng/mL
M-CSF and 5 ng/mL Receptor Activator of NF-κB Ligand
(RANKL, R&D Systems,Minneapolis, USA). The number of OCs
was assessed using tartrate-resistant acid phosphatase (TRAP)
staining (leucocyte acid phosphatase kit 387A, Sigma-Aldrich,
Darmstadt, GER). Number of OCs was counted using a light
microscope. TRAP+ cells with at least or more than three nuclei
were considered as being OCs. Each biological replicate has four
technical replicates.
Stimulation of CD14+ Monocytes
CD14+ monocytes were isolated and seeded at a density
of 1 × 105 cells/well in a 96-well plate and stimulated as
indicated with purified EV or Resiquimod - R848 (Invivogen,
San Diego, USA), diluted in Tris-EDTA (TE) buffer. Cells
were additionally treated with 200 nM of the TLR7/8 inhibitor
ODN 2088 Control (2087) (MiltenyiBiotec, Bergisch-Gladbach,
GER), diluted in TE buffer, 30min prior to stimulation with
EV or R848 at indicated experiments. Furthermore, cells
were treated either with 5 or 50 nM of synthetic miR-574-5p
(Sigma-Aldrich, Darmstadt, Germany) together with or without
1µg/ml Lipofectamine R© 2000 (Thermo Fisher Scientific,
Waltham, USA).
Cytokine mRNA Analysis
CD14+ monocytes were isolated and seeded at a density of
1 × 106 cells/well in a 12-well plate and stimulated either
with 1µg/ml purified scrambled control or miR-574-5p oe sEV
or 10 ng/ml R848 for 4 h. For experiments with the TLR7/8
inhibitor ODN 2088 Control (2087), cells were treated with
200 nM inhibitor 30min prior to stimulation with sEV or R848
positive control. The mRNA level of each cytokine was analyzed
by RT-qPCR.
Microscale Thermophoresis (MST)
The Cyanine5-labeled hsa-miR-574-5p (5′-
UGAGUGUGUGUGUGUGAGUGUGU [Cyanine5]-3′,
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Sigma-Aldrich, Darmstadt, GER) was adjusted to 100 nM
with PBS (pH7.4, Thermo Fisher Scientific, Waltham, USA)
supplemented with 0.05%Tween 20 (NanoTemper Technologies,
München, GER). A series of 16 1:2 dilutions was prepared with
recombinant human TLR8 (H00051311_G01, Abnova, Taiwan)
using the protein storage buffer (25mM Tris-HCl pH 8.2%
Glycerin), producing ligand concentrations ranging from 20.4
pM to 668 nM. For the measurement, each ligand dilution
was mixed with one volume of labeled hsa-miR-574-5p
which leads to a final concentration of hsa-miR-574-5p of
50 nM and final ligand concentrations ranging from 10.4
pM to 334 nM. After 5min incubation, the samples were
loaded into Monolith NT.115 Standard Treated Capillaries
(NanoTemper Technologies, München, GER). Instrument
parameters were adjusted to 60% LED power and 40% MST
power. A negative control was performed using Cy5-labeled hsa-
miR-16 (5′-UAGCAGCACGUAAAUAUUGGCG[Cyanine5]-3′,
Sigma-Aldrich, Darmstadt, GER) with a final concentration
of 50 nM and a final TLR8 concentration ranging from
6.36 pM to 209 nM. Instrument parameters were adjusted
to 20% LED power and 60% MST power. Data of three
independently measurements were analyzed (MO.Affinity
Analysis software version 2.1.3, NanoTemper Technologies,
München, GER) using the signal from an MST-on
time of 1.5 s.
Immunofluorescence
1 × 106 CD14+ cells were seeded on poly-L-lysine (Sigma-
Aldrich, Darmstadt, GER) coated glass coverslips (12mm,
Neolab, Heidelberg, GER) allowed to settle for 24 h. Cells
were fixed with 4% formaldehyde (FA, Carl Roth, Karlsruhe,
GER) for 10min. After washing 3 times for 3min with PBS,
cells were permeabilized with 0.5% Triton X-100 (Sigma-
Aldrich, Darmstadt, GER) in PBS for 10min. Subsequently,
cells were blocked with 4% BSA (Sigma-Aldrich, Darmstadt,
GER) in PBS for 20min. The primary antibodies against
TLR7 (MA5-16247, Invitrogen, ThermoFisher Scientific,
Waltham, USA) or TLR8 (PA5-20056, ThermoFisher Scientific,
Waltham, USA) were diluted 1:50 (TLR7) or 1:100 (TLR8) in
blocking solution and incubated for 1 h at room temperature.
Afterwards, cells were washed with 0.01% Tween20 (Carl
Roth, Karlsruhe, GER) in PBS 3 times for 5min and incubated
either with secondary antibody goat anti-mouse IgG (Alexa
Fluor R© 594, ab150116, abcam, Cambridge, UK) diluted
1:500 for TLR7 or goat anti rabbit IgG (Alexa Fluor R© 488,
111-454-144, JacksonImmunoResearch, Ely, UK) in blocking
solution for 45min at room temperature. Finally, cells were
washed with 0.01% Tween20 (Carl Roth, Karlsruhe, GER) in
PBS and counterstained with 4′,6-diamidine-2′-phenylindole
dihydrochloride (DAPI, Sigma-Aldrich, Darmstadt, GER) for
5min and mounted in 1,4-Diazabicyclo[2.2.2]octane (DABCO,
Sigma-Aldrich, Darmstadt, GER). Fluorescence microscopy
was carried out using a Zeiss Axiovert 200 microscope. Images
were taken with Plan-Apochromat 100x/NA 1.4 (pixel size
XY = 66 nm) oil immersion objective and a Zeiss AxioCam
mRM camera.
Fuorescences in-situ Hybridization of
miR-574-5p
2.5 × 105 CD14+ monocytes were seeded on 12mm glass
coverslips in a 24-well plate and differentiated into M2-like
macrophages by addition M-CSF to a final concentration of
25 ng/ml and further cultivation for 3 days.
Cells were fixed in formaldehyde (4% in PBS, 10min at room
temperature) followed by Trition X-100 permeabilization (0.5%
in PBS, 10min at room temperature), samples were washed
three times with PBS containing 0.01 % Tween20, respectively.
Coverslips where then placed at 37◦C for 30min covered with
1x miR ISH buffer (Qiagen, Hilden, GER, Cat No./ID: 339450)
for prehybridization. Coverslips where then transferred into a
hybridization chamber and covered with double DIG labeled
anti miR-574-5p probe (Qiagen, Hilden, GER, 100 nM in 1x
miR ISH buffer). Hybridization was carried out at 54◦C for 1 h.
Samples were transferred into a humidified staining chamber and
washed twice with 54◦C warm 2x SSC buffer (20x SSC stock
solution, Invitrogen Karlsruhe, GER). Blocking was performed
with 2% BSA (in PBS, 20min at room temperature). Antigen
detection was performed over night at 4◦C. Anti-miR-574-5p
DIG probe was detected by rabbit anti-DIG antibodies (Thermo
Fisher Scientific, Waltham, USA, 9H27L19, 1 ng/ml final, diluted
in blocking buffer) and TLR8 was detected by mouse anti-TLR8
antibodies (Thermo Fisher Scientific, Waltham, USA, 44C143,
1 ng/ml final, diluted in blocking buffer). Samples were washed
three times with PBS containing 0.01% Tween20. Primary
antibodies where detected using donkey anti-rabbit AlexaFluor
594 conjugated antibodies (abcam, Cambridge, UK, ab150080,
5 ng/ml final, diluted in blocking buffer) and donkey anti-mouse
AlexaFluor 488 conjugated antibodies (abcam, Cambridge, UK,
ab150105, 5 ng/ml final, diluted in blocking buffer) for 1 h at
room temperature. Samples were washed again three times with
PBS containing 0.01% Tween20. Nuclei where counterstained
using DAPI (Sigma-Aldrich, Darmstadt, GER, 1µg/ml, 10min
at room temperature). Samples were washed once with water and
mounted using Mowiol (Sigma Aldrich, Darmstadt, GER).
Statistics
Results are presented as mean+ SEM or± SD. Statistical analysis
was carried out using Student’s unpaired t-test (two-tailed) or
one-way ANOVA with turkey post-test using GraphPad Prism
6.0. Differences were considered as significant for p < 0.05
(indicated as ∗ for p < 0.05, ∗∗ for p < 0.01, ∗∗∗ for p < 0.001 and
∗∗∗∗ for p < 0.0001). Dixon’s test was performed as outlier test.
RESULTS
Isolation of sEV From Synovial Fluid of RA
Patients
We isolated sEV from the synovial fluid of RA patients
positive for anti-citrullinated protein antibodies (ACPA+), which
is associated with a more aggressive RA disease course and
enhanced bone resorption (19). The vesicles were isolated using
differential ultracentrifugation (Supplementary Figure 1A). The
morphology and the size of the isolated vesicles were determined
Frontiers in Immunology | www.frontiersin.org 4 October 2020 | Volume 11 | Article 585282
Hegewald et al. miR-574-5p Induces Osteoclast Differentiation
FIGURE 1 | Characterization of small extracellular vesicles (sEV). sEV were isolated by differential ultracentrifugation from serum, synovial fluid and HEK 293 cell
supernatants. (A) Transmission electron microscopy (TEM), scale bar 200 nm. (B) Western blot analysis of CD9, Hsp70, CD63, and CD81 (N = 3). Blots and TEM
pictures are shown from one representative experiment. (C) Schematic diagram of osteoclast (OC) differentiation. Cells were stimulated with sEV either at the
monocyte stage (day 1) or the M2-like macrophage stage (day 3) as indicated by the arrows (D,E) Tartrate-resistant acid phosphatase (TRAP) staining of mature OCs
obtained from CD14+ monocytes and cultured in presence of sEV derived from synovial fluid of two ACPA+ RA patients (1, 2, or 4µg/ml). sEV were added to (D)
CD14+ monocytes and to (E) M2-like macrophages. Multinucleated cells with three or more nuclei that were stained with a purple color were considered as OCs. The
relative changes are given as mean + SEM (N = 4), t-test **p < 0.01, ***p < 0.001, scale bar 50µm. Representative images of TRAP positive cells are shown. (F,G)
sEV miR level of miR-574-5p,−16-5p,−155-5p, and−146a-5p isolated from 500 µl serum (F) or 500 µl synovial fluid (G) from three RA patients. Before sEV isolation,
synovial fluid was pre-treated with hyaluronidase (1,500 U/ml) for 15min at 37◦C. MiR levels were determined by RT-qPCR and normalized to the spike-in control
cel-miR-39-3p (200 nM). Data are shown as the mean + SEM (N = 3). *p < 0.05.
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by TEM, showing that the isolated population had the typical
vesicular morphology and sEV size, ranging from 50 to 150 nm
(Figure 1A). Using Western blotting, we were able to detect
specific sEV surface protein markers such as CD63, CD9, Hsp70,
and CD81 in sEV lysates (Figure 1B) (8).
sEV Derived From Synovial Fluid of RA
Patients Induce Osteoclastogenesis
We next investigated whether sEV isolated from the synovial
fluid of ACPA+ RA patients influence osteoclastogenesis. CD14+
monocytes were separated from peripheral blood mononuclear
cells of healthy donors and stimulated with recombinant
human M-CSF, RANKL (20) in combination with different
concentrations of sEV (Figure 1C). In order to assess whether
there were time- and maturation stage-related differences, both
freshly isolated CD14+ monocytes and M2-like macrophages
(21) were treated with sEV (Figures 1D,E). After 9–12 days, cells
were fixed and stained for the OC marker TRAP. We observed a
significant dose-dependent increase (about 30%) in OC numbers,
when the sEV were applied to monocytes (Figure 1D). A similar
increase was observed, when macrophages, a later stage of
OC differentiation, were treated with sEV (Figure 1E). These
results suggest that the content of sEV derived from the
synovial fluid of RA patients may contribute to an increased OC
differentiation process.
Synovial Fluid Derived sEV Contain High
Levels of miR-574-5p
It is known that miRs are selectively packaged in extracellular
vesicles (22) and modulate inflammation and OC formation (23).
Therefore, we selected four different miRs (hsa-miR-146a-5p,
miR-155-5p, miR-16-5p and miR-574-5p) which previously have
been associated with inflammation and/or osteoclastogenesis (14,
24–28). RT-qPCR was performed to analyze the level of each
miR in sEV isolated from synovial fluid and in the corresponding
serum samples from three RA patients. In contrast to miR-146a-
5p, miR-16-5p and miR-155-5p, high levels of miR-574-5p were
detected in sEV isolated from synovial fluid and serum samples.
FIGURE 2 | Comparison of miR-574-5p, 16-5p, 155-5p, and 146a-5p levels in RA synovial fibroblasts (SFs). SFs from RA patients were cultured in sEV-depleted cell
culture medium for 24 h. Medium was replaced by sEV-depleted cell culture medium supplemented with either 10 ng/ml IL-1β, 10 ng/ml TNFα or both for 24 h. MiR
levels were determined by RT-qPCR. (A) Intracellular miR levels were normalized to snRNA U6 endogenous control. Data are shown as mean + SEM (N = 10), t-test
**p < 0.01. (B) MiR content in sEV derived from 1ml cell supernatant was determined by RT-qPCR normalized to the spike-in control cel-miR-39-3p (200 nM). Data is
shown as the mean + SEM of (N = 9). The results of (C) intracellular and (D) extracellular miR-574-5p were additionally evaluated with respect to patient
characteristics. Therefore, miR-574-5p levels of SFs cells derived from ACPA− RA patients (N = 5) or RA patients (N = 4) were normalized to the mean of ACPA−
patients. The relative changes are shown as the mean + SEM. *p < 0.05.
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FIGURE 3 | Effect of sEV delivered miR-574-5p on OC differentiation. (A) HEK 293 cells were transfected with scrambled control (ScrC) or over expressed
miR-574-5p (miR-574-5p oe) XMIRXpress construct. The sEV miR-574-5p level was analyzed by RT-qPCR and normalized to the spike-in control cel-miR-39-3p
(200 nM). Relative changes to ScrC control are presented as the mean + SEM (N = 4), t-test *p < 0.05. (B) miR-574-5p oe sEV were treated with 0.05 mg/ml RNase
(Continued)
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FIGURE 3 | A with and without 1% TritonX. MiR-574-5p level was determined by RT-qPCR and normalized to the spike-in control cel-miR-39-3p. Relative changes to
untreated sEV (w/o) are shown as the mean + SEM (N = 3), t-test **p < 0.01. (C) Purified miR-574-5p oe sEV were labeled with lipophilic tracer
3,3′-dioctadecyloxacarbocy-anine perchlorate (DiO) and added to CD14+ monocytes, which were stained with 5µg/ml Hoechst 33258. Images were taken every
10min, scale bar 10µm. (D–F) TRAP staining of mature OCs obtained from CD14+ monocytes. The cells were cultured in presence of 1µg/ml ScrC or miR-574-5p
oe sEV, which were added at (D) monocyte stage, (E) M2-like macrophage stage or (F) pre-osteoclast stage. TRAP-positive cells with three or more nuclei were
considered as OCs. The relative changes normalized to untreated control cells are given as mean + SEM (D,E) (N = 6) and (F) (N = 3), one-way ANOVA **p < 0.01,
***p < 0.001, ****p < 0.001, scale bar 50µm.
Notably, miR-146a was only detected once in sEV isolated from
synovial fluid, while the same miR was consistently present in
serum-derived sEV (Figures 1F,G).
Synovial Fibroblasts as Cellular Source of
sEV Derived miR-574-5p
SFs play a crucial role in the pathogenesis of RA (29, 30).
We therefore analyzed intracellular and corresponding sEV
levels of miR-574-5p released from RA derived SFs using
RT-qPCR and compared those to the levels of miR-146a-
5p,−155-5p and−16-5p. In order to mimic the inflammatory
environment of the inflamed joint, we stimulated SFs with
10 ng/ml IL-1β or 10 ng/ml TNFα alone or in combination for
24 h (Figures 2A,B). We observed that miR-155-5p, miR-16-5p,
or miR-574-5p levels did not change significantly in response
to IL-1β or TNFα stimulation. MiR-146a-5p was included in
our experiments as a positive control. This miR has been
reported to be strongly induced by IL-1β stimulation which our
experiments also confirmed (31). TNFα stimulation alone had
no influence on miR-146a-5p expression (Figure 2A). We next
isolated sEV from SF cell culture supernatants and performed
RT-qPCR. Very low levels of miR-155-5p or no miR-146a-5p
were found in sEV regardless of stimulation. In contrast, high
amounts of miR-16-5p and miR-574-5p were detected in the
sEV purified from both cytokine stimulated and unstimulated
SFs (Figure 2B), indicating that SFs are competent to secrete
miR-574-5p containing sEV in RA joints. In concordance with
a recent publication (32), we observed a slight but significant
increase in the number of sEV in response to both IL-1β and
TNFα stimulation (Supplementary Figures 1B,C).
Our next step was to compare intra- and extracellular miR-
574-5p levels with regard to patients’ ACPA status. No significant
differences were evident comparing the intracellular expression
ofmiR-574-5p in unstimulated SFs (Figure 2C). Contrary, higher
concentrations ofmiR-574-5p were observed in sEV generated by
SFs from ACPA+ compared to ACPA− patients (Figure 2D).
However, the extracellular level of miR-574-5p was
significantly higher in sEV derived from unstimulated SFs
from ACPA+ RA patients compared to SFs isolated from ACPA−
patients (Figure 2D).
Overexpression of miR-574-5p in sEV
To assess whether the elevated miR-574-5p level in sEV
had an influence on osteoclastogenesis, we established a miR
overexpression system in HEK 293 cells that enhanced miR-
574-5p loading into sEV (miR-574-5p oe sEV). For control
experiments, we used sEV loaded with a scrambled miR (ScrC
sEV). Comparing oe sEVwith ScrC sEV (Figure 3A), we detected
a ∼15-fold increase of miR-574-5p in the oe sEV. A RNase
protection experiment was performed by treating the sEV with
RNase alone or together with a detergent to determine if miR-
574-5p was loaded into the sEV or if it was only attached to the
sEV surface (33). The miR-574-5p was protected from RNase I
digestion unless detergent was added to disrupt the membrane
(Figure 3B). Therefore, we conclude that at least the majority
of miR-574-5p is selectively loaded into the oe sEV. Finally, we
could show that these sEV are taken up by cells like monocytes
(Figure 3C) and HeLa cells (Supplementary Figure 1D), using
confocal microscopic live cell imaging.
sEV With High miR-574-5p Levels Induce
Osteoclastogenesis
In order to investigate the role of sEV derived miR-574-5p during
osteoclastogenesis, we added either 1µg/ml miR-574-5p oe sEV
or ScrC sEV at different time points during OC differentiation
(Figures 3D–F). After ∼12 days of differentiation, the cells were
TRAP-stained and the number of OCs was counted.
When sEV were added at the stage of monocytes, a significant
upregulation of OC numbers was observed in response to
miR-574-5p oe sEV compared to ScrC sEV or untreated
control (Figure 3D). We observed comparable results, when
the engineered sEV were added at the stage of macrophages
(Figure 3E). No significant changes in OC numbers were found
when sEV were added to pre-OCs, neither with the addition of
control or miR-574-5p oe sEV (Figure 3F). These results suggest
that the effect of extracellular miR-574-5p strongly depends on
the maturation stage of the cells during OC differentiation.
Increased Osteoclast Differentiation by
miR-574-5p Is Mediated by TLR7/8
First hints indicating that miR-574-5p represents a novel TLR7/8
agonist (34) were based on its sequence homology to RNA33,
a well-known TLR7/8 ligand (35) (Figure 4A). To validate a
direct interaction between miR-574-5p and TLR8, MST (36)
was performed using Cy5-labeled miR-574-5p and commercially
available human recombinant TLR8.We observed strong binding
of miR-574-5p to TLR8 with a dissociation constant (KD) of 30.8
± 5.24 nM (Figures 4B,C). As negative control we used miR-
16-5p, a randomly chosen natural miR that contains no binding
sequence for TLR8 (Figure 4A), which shows no binding capacity
in MST analysis (Figures 4B,C).
We next investigated whether the increasedOC differentiation
was due to the activation of TLR7/8. During OC differentiation,
all cell types were stained positively for TLR7/8 expression
(Supplementary Figures 2A,B). Furthermore, occasional
colocalization between miR-574-5p and TLR8 was observed
in M2-like macrophages (Supplementary Figures 2C,D).
Therefore, we isolated and stimulated monocytes and
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FIGURE 4 | Increased OC differentiation by sEV-delivered miR-574-5p is mediated by TLR7/8 activation (A) Comparison of sequence homologies of miR-574-5p and
miR-16-5p to RNA33. (B,C) In microscale thermophoresis (MST) affinity assay of miR-574-5p to human recombinant TLR8, 50 nM of Cy5-labeled miR-574-5p and
334 nM−10.2 pM of non-labeled TLR8 were used. As negative control, 50 nM of Cy5-labeled hsa-miR-16-5p with 209 nM−6.36 pM of TLR8 were used. After a short
(Continued)
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FIGURE 4 | incubation, samples were loaded into Monolith NT.115 Standard Treated Capillaries and the MST measurement was performed (B) Dose response curve
reveals a KD of 30.8 ± 5.24 nM for the interaction of miR-574-5p and TLR8. Data are shown as ± SD (N = 3). (C) MST traces shown for miR-574-5p or miR-16-5p
and TLR8. An MST-on time of 1.5 s was used for analysis. (D–G) TRAP-positive OCs obtained from CD14+ monocytes cultured in presence of (D,E) 1µg/ml ScrC- or
miR-574-5p oe sEV together with 200 nM TLR7/8 inhibitor ODN 2087 or (F,G) 10–1,000 ng/ml - TLR7/8 ligand R848 added either at (D/F) monocyte stage or (E/G)
M2-like macrophage stage. TRAP-positive cells with three or more nuclei were considered as OCs. The relative changes normalized to untreated control cells are
given as mean + SEM (N = 4), one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.
macrophages with miR-574-5p oe sEV or ScrC sEV
together with 200 nM of the TLR7/8 inhibitor ODN 2087.
As expected, the miR-574-5p-mediated effect was completely
blocked by the addition of the inhibitor (Figures 4D,E;
Supplementary Figures 3A,B). As a control experiment we used
R848, a known TLR7/8 ligand (37, 38), which was added to the
monocytes and macrophages instead of sEV at a concentration
of 10 ng/ml in the same experimental setup. As previously
with miR-574-5p oe sEV, a significant increase of OC numbers
was observed (Figures 4F,G; Supplementary Figures 3C,D)
that was blocked using TLR7/8 inhibitor. No increase in
osteoclastogenesis was observed, when pre-OCs were stimulated
with the TLR7/8 agonist (Supplementary Figure 3E). This
result was consistent with the results with miR-574-5p oe sEV
or ScrC sEV (Figure 3F). Notably, we observed an increase
in OC differentiation, when monocytes or macrophages were
stimulated with the TLR7/8 ligand R4848. While the agonist led
to an increase inOCnumbers at low doses, the opposite effect was
observed at higher R848 concentrations. The number of OCs was
drastically reduced, when cells were treated with 1µg/ml R848
at all differentiation time points. The same negative effect was
observed when 100 ng/ml of R848 were added to macrophages
and pre-OCs (Figures 4F,G; Supplementary Figure 3E). In
summary, our results strongly suggest that the increase in
OC differentiation by sEV derived miR-574-5p is mediated by
TLR7/8 activation.
sEV Delivered miR-574-5p Induces IFNα
and IL-23 mRNA in CD14+-monocytes via
TLR7/8 Activation
We next aimed to understand which cytokines were increased
by sEV with high miR-574-5p levels. Therefore, we stimulated
CD14+ monocytes either with 4µg/ml of sEV isolated from
the synovial fluid of ACPA+ RA patients or with 1µg/ml
of miR-574-5p oe sEV or ScrC sEV for 4 h. Total RNA was
isolated and the mRNA levels of different TLR7/8 target genes
such as IL-23, IL-8, INFα, IL-1β, and TNFα were analyzed
(Figure 5; Supplementary Figure 4). These cytokines are known
to influence OC differentiation (39). We observed no changes
in IL-23 mRNA levels, while IFNα mRNA levels increased
about ∼3-fold, when cells were treated with sEV isolated from
synovial fluid (Figures 5A,B). When stimulating the monocytes
with miR-574-5p oe sEV, we observed significant 2- and 5-
fold inductions of IL-23 and IFNα mRNA, respectively, while
ScrC sEV had no effect (Figures 5C,D). The induction of IL-
23 and IFNα was reversed by additional application of the
TLR7/8 inhibitor. Comparable results were obtained when
monocytes were stimulated with 10 ng/ml of the TLR7/8 ligand
R848 (Figures 5E,F). In contrast to IL-23 and IFNα, the
mRNA levels of TNFα, IL-1β, and IL-8 were not significantly
affected by sEV isolated from the synovial fluid of RA patients
(Supplementary Figures 4A–C), miR-574-5p oe sEV or R848
(Supplementary Figures 4D–I).
DISCUSSION
sEV were identified as a key factor in cell-to-cell communication
through transfer of miRs (10, 22). A better understanding of
their physiological function in the synovial microenvironment of
RA patients is essential for the development of novel treatment
strategies. While previous studies have shown that extracellular
vesicles play an important role in the pathogenesis of RA (40),
the molecular mechanism and their impact on bone resorption
needs to be further elucidated. Our study shows for the first
time that sEV isolated from synovial fluid of RA patients caused
an increased OC differentiation, which we attribute to high
abundance of miR-574-5p in the sEV.
Different cell types in the joint microenvironment can
contribute to aggressive cartilage and bone resorption (1). In
particular, activated SFs strongly induce osteoclast formation
(29, 30). We identified SFs as a cellular source of sEV with
high miR-574-5p content. Despite the low number of patient-
derived synovial fibroblasts, we observed higher levels of miR-
574-5p in the sEV derived fromACPA+ compared to ACPA− RA
patients. Since ACPA positivity is associated with a more severe
and aggressive course of RA (19, 41), it is intriguing to propose
that miR-574-5p might play a role in ACPA+ RA. However, it is
for future studies to identify the source of high miR-574-5p levels
in ACPA+ RA patients and to investigate the potential impact of
ACPAs on miR-574-5p secretion into sEV.
In order to perform functional assays, we established an
overexpression system in which sEV were loaded with high
amounts of miR-574-5p. We demonstrated that miR-574-5p oe
sEV were taken up by cells and were physiologically active.
CD14+ monocytes and M2-like macrophages were stimulated
withmiR-574-5p oe sEV and significant changes inOC formation
were observed compared to controls. No changes were observed
when the same sEV were applied to pre-OCs, indicating that only
a certain progenitor cell stage is responsive to extracellular miR-
574-5p. Although all cell types show TLR7/8 expression, it can
be speculated that certain downstream proteins are induced in
pre-OCs which negatively regulate TLR signaling in response to
miR-574-5p stimulation (42).
Furthermore, it suggests that the sEV delivered miR-574-5p
might have immune-modulating functions. miRs have proven
to be regulators in immune response (43) via binding to TLRs
(15, 44, 45). sEV-delivered miR-let-7b is able to transform
human- and mouse naive monocytes into inflammatory M1-
like macrophages by activating TLR7 (44). This highlights the
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FIGURE 5 | Effect of sEV-delivered miR-574-5p on IL-23 and IFNα mRNA levels. CD-14+ monocytes were stimulated with (A,B) 4µg/ml sEV isolated from synovial
fluid of ACPA+ RA patients or (C,D) 1µg/ml of ScrC or miR-574-5p oe sEV and 200 nM ODN 2087. Cells were harvested after 4 h of incubation and total RNA was
extracted. Quantification of (A,C) IL-23 and (B,D) IFNα mRNA levels using RT-qPCR. (E,F) CD14+ monocytes were stimulated with 10 ng/µl R848 and 200 nM of
ODN 2087 for 4 h. Total RNA was extracted, and RT-qPCR was performed to quantify (E) IL-23 and (F) IFNα mRNA level. β-Actin was used as endogenous control.
Relative changes normalized to untreated controls are given as + SEM (N = 4), one-way ANOVA, *p < 0.05.
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importance of extracellular miRs in cell-to-cell communication
and their impact on chronic inflammatory diseases. However,
the mechanisms of extracellular miR release and their effects on
target cells are not fully understood.
In our experimental setup, we demonstrated that miR-574-
5p induces osteoclastogenesis only when loaded into sEV.
Synthetic liposomal vehicles or synthetic miRs alone had
no effect on osteoclastogenesis (Supplementary Figures 5A,B).
These findings are in agreement with current understanding that
vesicle-associated miRs are important players in the cell-to-cell
communication, while free miRs may only represent cell by-
products without physiological impact. We can speculate that
sEV uptake depends on proteins and glycoproteins expressed
on the surface of the vesicle as well as on the surface of the
target cell (46). Furthermore, Fabbri et al., demonstrated that
extracellular vesicle-delivered miR-21 and−29a bind to human
TLR8 and trigger downstream to NF-κB activation in the context
of non-small cell lung cancer (15). Since miR-574-5p has a high
sequence analogy to the TLR7/8 ligand RNA33 and induced
phosphorylation of the p65 subunits of NF-κB (15, 34, 35), we
asked whether miR-574-5p might act as direct TLR7/8 ligand
and increases OC differentiation by TLR7/8 activation. With
the results of our MST binding test and our experiments using
the TLR7/8 inhibitor ODN 2087 and the agonist R848, we
could show that miR-574-5p binds to the receptor and thus
mediates increased OC formation via TLR7/8. However, our
results seem to contradict a previous study by Miyamoto et al.,
which reports a decrease in OC formation in response to R848
stimulation (47). This inconsistency could be explained by slight
experimental differences such as the R848 concentration and the
cell types used to analyze the OCmaturation process. Our results
indicate that sEV delivered miR-574-5p has the highest influence
on osteoclastogenesis at monocyte and M2-like macrophage
stages compared to the pre-OC stage. This is probably due to
the binding of miR-574-5p to TLR7/8 whose expression level
is reduced during the monocyte differentiation process (48).
In addition, our results are supported by findings of Salvi
et al., who showed that extracellular miR-574-5p can promote
production of IFNα by inducing human TLR7 activation in
human plasmacytoid dendritic cells (34). In fact, we observed
similar results when we treated monocytes with miR-574-5p
oe sEV stimulation or TLR7/8 ligand R848. In both cases,
we observed an increase in IFNα and IL-23 mRNA levels.
Extracellular miR-574-5p can therefore be considered as a new
immune-modulating mediator which strongly influences bone
resorption in RA via its function as TLR7/8 ligand.
Additionally, it has recently been shown that an elevated
intracellular miR-574-5p expression is directly associated with
an enhanced synthesis of prostaglandin E2 (14), an important
pro-inflammatory lipid mediator which mediates inflammation
in RA (49). This newly discovered link between miR-574-
5p, inflammation and OC-mediated bone resorption offers the
opportunity to develop new RNA-therapeutics. Inhibitors against
miR-574-5p would address simultaneously its intracellular
function as a regulator of prostaglandin synthesis and its
endosomal function as TLR7/8 ligand, which would inhibit bone
resorption in arthritis disease such as RA.
DATA AVAILABILITY STATEMENT
All datasets presented in this study are included in the
article/supplementary material.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by the Institutional Ethical Committee (Solna,
Stockholm, Sweden, the ethical permit number 2009/1262-
31/3) and is in compliance with all ethical standards and
patients’ consent according to the Declaration of Helsinki. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
AH performed the biochemistry experiments, analyzed the data,
and wrote the manuscript. KB performed the colocalization
staining, supported the experiments, and contributed to writing.
SO performed the MST analysis and supported the experiments.
FM performed the FACS analysis. MK, P-JJ, AC, and HW
provided patient material. BR and HW designed and supported
the experiments. HW contributed to writing. MS conceived the
study, designed and supervised the overall project, and wrote the
manuscript. All authors conducted the quality assurance of the
paper and reviewed the manuscript.
FUNDING
This project was supported by Else Kröner-Fresenius Stiftung
(2013_A265), Boehringer Ingelheim Fond (Travel grant; grant
no.: n/a), Athene Young Investigator program (Technische
Universität Darmstadt; grant no.: n/a), Dr. Ing. Wilhelm und
Maria Kirmser-Stiftung (grant no.: n/a), LOEWE-Zentrum
Translationale Medizin und Pharmakologie (Innovationsfond)
and the Swedish Rheumatism Association (grant no.: n/a).
We acknowledge support by the German Research Foundation
and the Open Access Publishing Fund of Technical University
of Darmstadt.
ACKNOWLEDGMENTS
We are grateful to M. Cristina Cardoso (TU Darmstadt,
Germany) for providing access to her MST and microscope
facilities and to Beatrix Suess (TU Darmstadt), Dieter
Steinhilber (Goethe Universität Frankfurt, Germany), and
Bianca Bertulat (TU Darmstadt) for scientific support. We
thank, Bob Harris (Karolinska Institutet), Anne C. Emmerich,
and Julia Wellstein (both TU Darmstadt) for discussion and
proof reading.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.585282/full#supplementary-material
Frontiers in Immunology | www.frontiersin.org 12 October 2020 | Volume 11 | Article 585282
Hegewald et al. miR-574-5p Induces Osteoclast Differentiation
REFERENCES
1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. (2003)
423:356–61. doi: 10.1038/nature01661
2. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms,
diagnosis and treatment. Nat Rev Rheumatol. (2012) 8:656–64.
doi: 10.1038/nrrheum.2012.153
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation.
Nature. (2003) 423:337–42. doi: 10.1038/nature01658
4. Karsenty G, Kronenberg HM, Settembre C. Genetic control of
bone formation. Annu Rev Cell Dev Biol. (2009) 25:629–48.
doi: 10.1146/annurev.cellbio.042308.113308
5. Foers AD, Chatfield S, Dagley LF, Scicluna BJ, Webb AI, Cheng L,
et al. Enrichment of extracellular vesicles from human synovial fluid
using size exclusion chromatography. J Extracell Vesicles. (2018) 7:1490145.
doi: 10.1080/20013078.2018.1490145
6. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology
of extracellular vesicles. Nat Rev Mol Cell Biol. (2018) 19:213–28.
doi: 10.1038/nrm.2017.125
7. Fu H, Hu D, Zhang L, Tang P. Role of extracellular vesicles in rheumatoid
arthritis.Mol Immunol. (2018) 93:125–32. doi: 10.1016/j.molimm.2017.11.016
8. Thery C,Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina
R, et al. Minimal information for studies of extracellular vesicles 2018.
(MISEV2018): a position statement of the International Society for
Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell
Vesicles. (2018) 7:1535750. doi: 10.1080/20013078.2018.1535750
9. Beyer C, Pisetsky DS. The role of microparticles in the
pathogenesis of rheumatic diseases. Nat Rev Rheumatol. (2009) 6:21.
doi: 10.1038/nrrheum.2009.229
10. Penfornis P, Vallabhaneni KC, Whitt J, Pochampally R. Extracellular vesicles
as carriers of microRNA, proteins and lipids in tumor microenvironment. Int
J Cancer. (2016) 138:14–21. doi: 10.1002/ijc.29417
11. Ambros V. The functions of animal microRNAs. Nature. (2004) 431:350–5.
doi: 10.1038/nature02871
12. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by
microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci
USA. (2007) 104:9667–72. doi: 10.1073/pnas.0703820104
13. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, et al. miR-
328 functions as an RNA decoy to modulate hnRNP E2 regulation
of mRNA translation in leukemic blasts. Cell. (2010) 140:652–65.
doi: 10.1016/j.cell.2010.01.007
14. Saul MJ, Baumann I, Bruno A, Emmerich AC, Wellstein J, Ottinger
SM, et al. miR-574-5p as RNA decoy for CUGBP1 stimulates human
lung tumor growth by mPGES-1 induction. FASEB J. (2019) 33:6933–47.
doi: 10.1096/fj.201802547R
15. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R,
et al. MicroRNAs bind to Toll-like receptors to induce prometastatic
inflammatory response. Proc Natl Acad Sci USA. (2012) 109:E2110–6.
doi: 10.1073/pnas.1209414109
16. Leclerc P, Wahamaa H, Idborg H, Jakobsson PJ, Harris HE, Korotkova
M. IL-1beta/HMGB1 complexes promote The PGE2 biosynthesis
pathway in synovial fibroblasts. Scand J Immunol. (2013) 77:350–60.
doi: 10.1111/sji.12041
17. Saul MJ, Stein S, Grez M, Jakobsson PJ, Steinhilber D, Suess B.
UPF1 regulates myeloid cell functions and S100A9 expression by the
hnRNP E2/miRNA-328 balance. Sci Rep. (2016) 6:31995. doi: 10.1038/srep
31995
18. Fauth M, Hegewald AB, Schmitz L, Krone DJ, Saul MJ. Validation of
extracellular miRNA quantification in blood samples using RT-qPCR. FASEB
BioAdv. (2019) 1:481–92. doi: 10.1096/fba.2019-00018
19. Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard
S, et al. Prediction of radiographic progression in rheumatoid arthritis
and the role of antibodies against mutated citrullinated vimentin: results
from a 10-year prospective study. Ann Rheum Dis. (2010) 69:345–51.
doi: 10.1136/ard.2009.113092
20. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human
primary osteoclasts: in vitro generation and applications as pharmacological
and clinical assay. J Transl Med. (2004) 2:6. doi: 10.1186/1479-5876-2-6
21. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling
of the human monocyte-to-macrophage differentiation and polarization: new
molecules and patterns of gene expression. J Immunol. (2006) 177:7303–11.
doi: 10.4049/jimmunol.177.10.7303
22. Bayraktar R, Van Roosbroeck K, Calin GA. Cell-to-cell communication:
microRNAs as hormones. Mol Oncol. (2017) 11:1673–86.
doi: 10.1002/1878-0261.12144
23. Adamopoulos IE. Inflammation in bone physiology and pathology. Curr Opin
Rheumatol. (2018) 30:59–64. doi: 10.1097/BOR.0000000000000449
24. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T,
et al. Exosome-delivered microRNAs modulate the inflammatory response to
endotoxin. Nat Commun. (2015) 6:7321. doi: 10.1038/ncomms8321
25. Dunaeva M, Blom J, Thurlings R, Pruijn GJM. Circulating serum miR-223-3p
and miR-16-5p as possible biomarkers of early rheumatoid arthritis. Clin Exp
Immunol. (2018) 193:376–85. doi: 10.1111/cei.13156
26. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel
K, et al. Tumor-induced osteoclast miRNA changes as regulators and
biomarkers of osteolytic bone metastasis. Cancer Cell. (2013) 24:542–56.
doi: 10.1016/j.ccr.2013.09.008
27. Pauley KM, Cha S. miRNA-146a in rheumatoid arthritis: a new therapeutic
strategy. Immunotherapy. (2011) 3:829–31. doi: 10.2217/imt.11.70
28. Su LC, Huang AF, Jia H, Liu Y, XuWD. Role of microRNA-155 in rheumatoid
arthritis. Int J Rheum Dis. (2017) 20:1631–7. doi: 10.1111/1756-185X.13202
29. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts:
key players in rheumatoid arthritis. Rheumatology. (2006) 45:669–75.
doi: 10.1093/rheumatology/kel065
30. Lefevre S, Meier FM, Neumann E, Muller-Ladner U. Role of synovial
fibroblasts in rheumatoid arthritis. Curr Pharm Des. (2015) 21:130–41.
doi: 10.2174/1381612820666140825122036
31. Stanczyk J, Pedrioli DML, Brentano F, Sanchez-pernaute O, Kolling C,
Gay RE, et al. Altered expression of MicroRNA in synovial fibroblasts and
synovial tissue in rheumatoid arthritis. Arthritis Rheumat. (2008) 58:1001–9.
doi: 10.1002/art.23386
32. Kato T, Miyaki S, Ishitobi H, Nakamura Y, Nakasa T, Lotz MK, et al.
Exosomes from IL-1 β stimulated synovial fibroblasts induce osteoarthritic
changes in articular chondrocytes. Arthritis Res Ther. (2014) 16:R163.
doi: 10.1186/ar4679
33. ShurtleffMJ, Temoche-diazMM, Karfilis KV, Ri S, Schekman R. Y-box protein
1 is required to sort microRNAs into exosomes in cells and in a cell-free
reaction. eLife. (2016) 5:e19276. doi: 10.1101/040238
34. Salvi V, Sozzani S, Bosisio D, Salvi V, Gianello V, Busatto S, et al. Exosome-
delivered microRNAs promote IFN- a secretion by human plasmacytoid DCs
via TLR7. JCI Insight. (2018) 3:e98204. doi: 10.1172/jci.insight.98204
35. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al.
Species-specific recognition of single-stranded RNA via toll-like receptor 7
and 8. Science. (2004) 303:1526–9. doi: 10.1126/science.1093620
36. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. Protein-binding assays
in biological liquids using microscale thermophoresis. Nat Commun. (2010)
1:100. doi: 10.1038/ncomms1093
37. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small
anti-viral compounds activate immune cells via the TLR7 MyD88-dependent
signaling pathway. Nat Immunol. (2002) 3:196–200. doi: 10.1038/ni758
38. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al.
Human TLR7 or TLR8 independently confer responsiveness to the antiviral
compound R-848. Nat Immunol. (2002) 3:499. doi: 10.1038/ni0602-499
39. Amarasekara DS, Yun H, Kim S, Lee N, Rho J. Regulation of osteoclast
differentiation by cytokine networks. Immune Netw. (2018) 18:1–18.
doi: 10.4110/in.2018.18.e8
40. Withrow J,Murphy C, Liu Y, HunterM, Fulzele S, HamrickMW. Extracellular
vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthrit
Res Ther. (2016) 18:286. doi: 10.1186/s13075-016-1178-8
41. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. (2010)
376:1094–108. doi: 10.1016/S0140-6736(10)60826-4
42. Anwar MA, Basith S, Choi S. Negative regulatory approaches to the
attenuation of Toll-like receptor signaling. Exp Mol Med. (2013) 45:e11.
doi: 10.1038/emm.2013.28
43. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system
logic. Nat Rev Immunol. (2016) 16:279. doi: 10.1038/nri.2016.40
Frontiers in Immunology | www.frontiersin.org 13 October 2020 | Volume 11 | Article 585282
Hegewald et al. miR-574-5p Induces Osteoclast Differentiation
44. Kim S-j, Chen Z, Essani AB, Elshabrawy HA, Volin MV, Volkov S,
et al. Identification of a novel toll-like receptor 7 endogenous ligand
in rheumatoid arthritis synovial fluid that can provoke arthritic joint
inflammation. Arthrit Rheumatol. (2016) 68:1099–110. doi: 10.1002/art.
39544
45. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart
J, et al. An unconventional role for miRNA: let-7 activates Toll-like
receptor 7 and causes neurodegeneration. Nat Neurosci. (2012) 15:827–35.
doi: 10.1038/nn.3113
46. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular
vesicle uptake. J Extracell Vesicles. (2014) 3:24641. doi: 10.3402/jev.v3.24641
47. Miyamoto A, Takami M, Matsumoto A, Mochizuki A, Yamada T,
Tachi K, et al. R848, a toll-like receptor 7 agonist, inhibits osteoclast
differentiation but not survival or bone-resorbing function of mature
osteoclasts. Cytotechnology. (2012) 64:331–9. doi: 10.1007/s10616-012-
9442-5
48. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM, et al.
Regulation of toll-like receptors in human monocytes and dendritic cells. J
Immunol. (2001) 166:249–55. doi: 10.4049/jimmunol.166.1.249
49. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, et al.
Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis
synovium. Arthritis Rheumat. (2004) 50:1774–80. doi: 10.1002/art.20286
Conflict of Interest: MS and AH have submitted a patent application (DE
102019122014.9) “Inhibition of miR-574-5p as novel therapeutic strategy to
reduce bone resorption in arthritis disease.”
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Hegewald, Breitwieser, Ottinger, Mobarrez, Korotkova, Rethi,
Jakobsson, Catrina, Wähämaa and Saul. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 14 October 2020 | Volume 11 | Article 585282
